Ernexa Therapeutics (ERNAW) Return on Sales (2010 - 2024)

Ernexa Therapeutics has reported Return on Sales for 14 years, with the latest figure at 20.42% in Q4 2024.

• For the quarter ending Q4 2024, Return on Sales rose 2167.0% year-over-year to 20.42%; the trailing twelve-month figure through Dec 2024 stood at 0.0% (up 217.0% YoY), and the FY2024 full-year result was 0.0%, up 217.0% from the prior year.
• Return on Sales for Q4 2024 stood at 20.42%, up from 0.55% in the prior quarter.
• The five-year high for Return on Sales was 20.42% in Q4 2024, with the low at 1.41% in Q1 2024.
• Historically, Return on Sales has averaged 1.23% across 4 years, with a median of 0.13% in 2022.
• Annual changes were most pronounced in 2023 — Return on Sales plunged 128 bps — and 2024, when it surged 2167 bps.
• Ernexa Therapeutics' Return on Sales stood at 0.02% in 2020, then tumbled by 323 bps to 0.09% in 2022, then tumbled by 1253 bps to 1.25% in 2023, then soared by 1731 bps to 20.42% in 2024.
• The last three Return on Sales figures came in at 20.42% (Q4 2024), 0.55% (Q3 2024), and 1.18% (Q2 2024), per Business Quant data.